Evaxion Biotech A/S
EVAX
Rank in Stocks
#26982
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Share Price
$2.75
Last synced: 2026-11-09
Market Cap
$17.37M
Change (1 day)
-8.33%
Change (1 year)
-54.47%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Evaxion Biotech A/S (EVAX)
Category
Healthcare
EPS for Evaxion Biotech A/S (EVAX)
EPS as of June 2026 TTM: $-6.20
According to Evaxion Biotech A/S's latest financial reports, its current EPS (TTM) is $-6.20. At the end of 2025 the company had an EPS of $-1.21, an increase over its 2024 EPS of $-9.80.
EPS history for Evaxion Biotech A/S from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-6.20 | 412.40% |
| 2025 | $-1.21 | -87.65% |
| 2024 | $-9.80 | -69.75% |
| 2023 | $-32.40 | -17.35% |
| 2022 | $-39.20 | -22.22% |
| 2021 | $-50.40 | 36.22% |
| 2020 | $-37.00 | 34.06% |
| 2019 | $-27.60 | 139.58% |
| 2018 | $-11.52 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -352.58% |
US
|
|
| $-7.07 | 14.03% |
US
|
|
| $-5.29 | -14.68% |
AU
|
|
| $12.88 | -307.74% |
BE
|
|
| $21.56 | -447.74% |
NL
|
Questions about Evaxion Biotech A/S's earnings per share (EPS)
What is Evaxion Biotech A/S's earnings per share (EPS)?
Evaxion Biotech A/S's earnings per share (EPS) over the last twelve months is $-6.20, as of Jun 2026.
What was Evaxion Biotech A/S's earnings per share (EPS) in 2025?
In 2025, Evaxion Biotech A/S's earnings per share (EPS) was $-1.21, compared with $-9.80 in 2024.
How has Evaxion Biotech A/S's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Evaxion Biotech A/S's earnings per share (EPS) was highest in 2025 ($-1.21) and lowest in 2021 ($-50.40).
How does Evaxion Biotech A/S's earnings per share (EPS) compare with similar companies?
Evaxion Biotech A/S's earnings per share (EPS) ($-6.20) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.